KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Change in Receivables (2016 - 2025)

AbbVie (ABBV) has disclosed Change in Receivables for 14 consecutive years, with -$162.0 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 58.14% to -$162.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 billion through Dec 2025, up 819.81% year-over-year, with the annual reading at $1.5 billion for FY2025, 819.81% up from the prior year.
  • Change in Receivables for Q4 2025 was -$162.0 million at AbbVie, down from $156.0 million in the prior quarter.
  • The five-year high for Change in Receivables was $1.5 billion in Q1 2025, with the low at -$590.0 million in Q3 2021.
  • Average Change in Receivables over 5 years is $199.6 million, with a median of $118.0 million recorded in 2023.
  • Peak annual rise in Change in Receivables hit 260.0% in 2024, while the deepest fall reached 17100.0% in 2024.
  • Over 5 years, Change in Receivables stood at $749.0 million in 2021, then plummeted by 44.46% to $416.0 million in 2022, then crashed by 181.49% to -$339.0 million in 2023, then dropped by 14.16% to -$387.0 million in 2024, then soared by 58.14% to -$162.0 million in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at -$162.0 million, $156.0 million, and $17.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.